{"id":622310,"date":"2024-06-24T21:14:46","date_gmt":"2024-06-25T01:14:46","guid":{"rendered":"https:\/\/platohealth.ai\/deals-report-roche-licenses-ascidians-rna-editing-tech-for-neuro\/"},"modified":"2024-06-25T18:12:48","modified_gmt":"2024-06-25T22:12:48","slug":"deals-report-roche-licenses-ascidians-rna-editing-tech-for-neuro","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/deals-report-roche-licenses-ascidians-rna-editing-tech-for-neuro\/","title":{"rendered":"Deals Report: Roche licenses Ascidian\u2019s RNA editing tech for neuro","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

ARTICLE | Deals<\/p>\n

\n
\n
\n

Plus: Day One adds PTK7 ADC from MabCare, and updates from Sanofi<\/a>-Belharra and more<\/h2>\n

\n By Gunjan Ohri, Data Content Analyst<\/span><\/span>\n<\/p>\n

June 25, 2024 1:14 AM UTC<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/span><\/span><\/div>\n

The past seven days brought at least two deals that could be worth over $1 billion, with Roche gaining access to a RNA editing technology from Ascidian, and Day One adding an antibody-drug conjugate (ADC) from MabCare.<\/p>\n

Roche <\/b>(SIX:ROG; OTCQX:RHHBY) paid $42 million up front to use<\/span>  Ascidian Therapeutics Inc.<\/a><\/b>\u2019s RNA exon editing platform to create therapies against undisclosed neurological disease targets. Ascidian\u2019s technology<\/span> enables correction of disease-causing mutations via pre-mRNA trans-splicing<\/a>, which promises durable results while avoiding the risks of permanently altering the DNA via conventional gene editing. Ascidian, which is eligible for up to $1.8 billion in milestones, will conduct discovery and certain preclinical activities with Roche, after which the pharma will take over…<\/p>\n